Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer

NCT01222572 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Slow accrual due to restrictive eligibility criteria

Conditions

Non-small Cell Lung Cancer
Lung Cancer
NSCLC

Interventions

RADIATION: Stereotactic boost
RADIATION: Conventional RT
DRUG: Etoposide
DRUG: Cisplatin

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]